Matching-Adjusted Indirect Comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-Cell lymphoma in China

Background Mitoxantrone hydrochloride liposome (PLM60) is a novel liposome formulation, approved in China for the treatment of patients diagnosed with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This study aimed to assess the cost-effectiveness of PLM60 versus chidamide (CS055) in R/R PTCL from the Chinese healthcare perspective.